46 results
8-K
SYBX
Synlogic Inc
12 Feb 24
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
4:00pm
a reduction in workforce by approximately 90%. The decision was based on cost-reduction initiatives intended to reduce the Company’s ongoing operating expenses … in workforce by the end of the fiscal quarter ending March 31, 2024. The Company estimates that it will incur approximately $6 million of costs
8-K
EX-99.1
SYBX
Synlogic Inc
12 Feb 24
Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update
4:00pm
, and reduce its workforce by more than 90%, retaining only certain employees to assist in the strategic review and assist in the discontinuation
8-K
n0m hconwcfm
5 Jun 23
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
8:32am
8-K
EX-99.1
48k 3dtil
5 Jun 23
Synlogic Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria
8:32am
PRE 14A
r8zynk0px
21 Apr 23
Preliminary proxy
4:00pm
8-K
5ohibt3rf0
30 Nov 22
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
4:20pm
8-K
EX-99.1
0sugaeo
30 Nov 22
Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update
4:20pm